Bristol-Myers Squibb Co [ NYSE: BMY ]Bristol-Myers Squibb Co Pending Order Placement Entry Placement 63.18 Take Profit Placement 68.43 Stop Loss Placement 59.68by UnknownUnicorn18038843
BMY is worth buyingBristol-Myers Squibb says it has seen no major business disruptions and expects no decrease in global demand for its drugs this year. That means the 3.5% dividend yield should stay stable, and BMY is a great value at 1.3 PEG. BMY also just got FDA approval for a multiple sclerosis drug, which could turn out to be a pretty big deal. Most of the market has been trading based on macroeconomics, but as individual companies like BMY issue quantitative guidance, I think we're going to see more trading on company specifics. I bought a small position here and will add the dip if BMY heads south with the rest of the market next week.Longby ChristopherCarrollSmithUpdated 8828
Darvas Box BreakoutLast Thursday BMY closed on what looked like a Darvas Box breakout, but it wasn't a buy Fri. because it looked like a fake-out. Today it is still breaking upward, so it's looks like a buy after not retreating from the morning highLongby Ron-V6
$Bristol Myers Squibb All Time High TradeEntry level $66.60 = Target price $77.00 = Stop loss $64.50 Areas of interest/resistance $69.55 & $74.14 P/e ratio 18.77 Company profile Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.Longby Bullishcharts1138
$BMY Bristol Myers trade level The stock is on a bullish trajectory towards resistance at $64.60 but is lacking in volume and needs a little rotation to take place. Still trading at a very reasonable 17 P/E ratio. Yield attractive at 3%. Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.Longby RedHotStocks21
BMY oh boy , feels like this one is about show some money on 26 it is a sleeper , but profit margin of 24% is one of the best in its own class , very bullish here .. on chart at list :D posting my opinion only, never trade money you need to buy food and pay bills .. Happy trading ! Longby mralexsell5
i30.Bristol-Myers Squibb Beta-R:Journal. Risk Management: Compound .Level : PA . Time: Short-term - Intermediate . This is just my view follow if it aligns with yours. Ideas are not repeated rather updated.Worry about risk only.Shortby UnknownUnicorn43302921
$BMY beats but needs a pullback for entry. Bristol-Myers Squibb (NYSE:BMY) Q3 results: Revenues: $6,007M (+5.6%); product sales: $5,768M (+6.2%). Key product sales: Eliquis: $1,928M (+22.3%); Opdivo: $1,817M (+1.3%); Orencia: $767M (+13.6%); Sprycel: $558M (+13.6%); Yervoy: $353M (-7.6%). Net income: $1,366M (-28.6%); EPS: $0.83 (-28.4%); non-GAAP EPS: $1.17 (+7.3%). 2019 guidance: EPS: $3.46 - 3.56 from $3.73 - 3.83; non-GAAP EPS: $4.25 - 4.35 from $4.20 - 4.30. Source seeking Alpha Possible entry level $54-$57 with $63 as target and strong resistance. P/E ratio 14.94 - undervalued. Short interest high at 9.16%. Company profile Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.Longby Bullishcharts30
Nice Long For Earnings""For Bristol-Myers, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +0.38%. On the other hand, the stock currently carries a Zacks Rank of #3. So, this combination indicates that Bristol-Myers will most likely beat the consensus EPS estimate.....For the last reported quarter, it was expected that Bristol-Myers would post earnings of $1.06 per share when it actually produced earnings of $1.18, delivering a surprise of +11.32%.Over the last four quarters, the company has beaten consensus EPS estimates four times." (Zacks)Longby Ron-V3
Inverted Hammer Show Top for BMY?BMY gap-up today opening near $60 level, but closed at $54.23 creating somewhat an inverted hammer candle. Need to be cautious here. Stochastic still on the overbought territory. Watch the Stochastic closely for any sign dipping below 80 level. A closed below or near $53 we may consider to go square. by mukhriz.mangsor2
$BMY Bullish break imminent in Bristol-MyersTrading at a very low 13.77 P/E ratio. Short interest is quiet high at 9.15%, which could ignite a rally. Bristol-Myers Squibb resumed with Buy rating and $60 (16% upside) price target at BofAML. Company profile Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.by RedHotStocks16